Fifty‐two‐week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon‐like peptide‐1 analog liraglutide vs glibenclamide in patients with type 2 diabetes

Aims/Introduction:  We compared the safety and efficacy of liraglutide vs glibenclamide in patients with poorly controlled (HbA(1c), 7.4–10.4%) type 2 diabetes. Materials and Methods:  Subjects were randomly assigned at a 1:2 ratio to receive 1‐year treatment with glibenclamide 1.25–2.5 mg/day or li...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaku, Kohei, Rasmussen, Mads Frederik, Nishida, Tomoyuki, Seino, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014903/
https://www.ncbi.nlm.nih.gov/pubmed/24843528
http://dx.doi.org/10.1111/j.2040-1124.2011.00128.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014903/
https://www.ncbi.nlm.nih.gov/pubmed/24843528
http://dx.doi.org/10.1111/j.2040-1124.2011.00128.x

Ejemplares similares